Topline phase 3 ARISE trial results show oral solengepras 150mg significantly reduces OFF time and improves motor/non-motor function in Parkinson disease.
Functional decline begins many years before clinically apparent cardiovascular disease (CVD) events, according to a study published online Sept. 23 in JAMA Cardiology. Aung Zaw Zaw Phyo, Ph.D., from ...
Projections show that the aggregate surgeon supply will decline by 2038, leading to a lower national workforce adequacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results